FPH
data caveat$18.0BCF+
Fisher & Paykel Healthcare
Sleep & respiratory
Humidification and respiratory support devices; obstructive sleep apnea therapy systems
Data HealthTrials16 of 19 active · stale enrollment
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$0.0M
Dec 2025 4C
Runway
CF+Cash Flow Positive
Based on Dec 2025 4C
Market Cap
$18.0B
Burn Rate
—
Dec 2025 4C
Shares Outstanding
587M
Pipeline Assets
4
Latest Insight(1)
26 Mar 2026substantial_holderChange in substantial holding
Changed·BlackRock, Inc. and related bodies corporate·7.616%
3M Price
FPH.ASX$30.630-8.3% 3M
Low $30.000High $34.700
Pipeline Assets (4)
OptiflowNasal high flow oxygen therapy
ApprovedAIRVO 3Humidified high flow therapy system
ApprovedEvora FullObstructive sleep apnea (full-face mask)
ApprovedF&P 950Invasive ventilation humidification
ApprovedDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Substantial Holders (5%+ threshold)
4 noticesarrow_drop_upBlackRock, Inc. and related bodies corporate
7.62%2026-03-25
arrow_drop_upBlackRock, Inc. and related bodies corporate
7.62%2026-03-25
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
1 competitor trialPhase 2+ · Non-ASX
Nasal High Flow Oxygen Therapy1 active trial
1 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
2 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Ann R Coll Surg Engl2026-04· Optiflow
Int J Chron Obstruct Pulmon Dis2026-01
Catalysts (79)· 9 upcoming · 70 past
SpeculativeremoveMed1 May 2026
SpeculativeremoveMed1 July 2026
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Filing discipline not scored — this company reports under US regime (Form 10-K / 10-Q). ASX Listing Rule 4.7C deadlines don't apply.
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
★ RESULTS
Clinical Trials(40)
19 activeClinicalTrials.gov ↗
NARecruitingEnrollment stale · 716d
Investigational full-face mask with expiratory washoutConventional full-face mask - single-limbConventional full-face mask - dual-limb
Pilot Physiological Evaluation of an Investigational Mask with Expiratory Washout.
Acute Hypercapnic Respiratory Failure · Acute Hypoxemic Respiratory Failure
RandomizedSingle Blind18 Years+
Primary endpoint Minute Ventilation
NARecruitingEnrollment stale · 200d
Airvo 3
A Trial Comparing High-Flow Nasal Cannula Versus Noninvasive Ventilation on Reintubation and Post-Extubation Respiratory Failure in High-Risk Patients With Systolic Heart Failure
Systolic Heart Failure · Respiratory Failure
RandomizedOpen Label18 Years+
Primary endpoint Incidence of participants with reintubation or respiratory failure within 72 hours post-extubation
NARecruitingEnrollment stale · 105d
Closed loop oxygen controlManual titration
Closed Loop Oxygen Control in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Nasal High Flow in the Hospital
COPD
RandomizedOpen Label22 Years+
Primary endpoint Percentage of time with SpO2 in target range over period of observation